Section Arrow
Quote
MDGL.NASDAQ
- Madrigal Pharmaceuticals
Quotes are at least 15-min delayed:2026/05/31 11:20 EDT
Regular Hours
Last
 497.27
-18.69 (-3.62%)
Day High 
520.305 
Prev. Close
515.96 
1-M High
559 
Volume 
436.01K 
Bid
496.66
Ask
511.5
Day Low
496.625 
Open
514.57 
1-M Low
490.13 
Market Cap 
11.90B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 520.99 
20-SMA 518.64 
50-SMA 512.12 
52-W High 615 
52-W Low 265.2 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-13.49/7.01
Enterprise Value
12.24B
Balance Sheet
Book Value Per Share
23.57
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
958.40M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.1172-0.0468-28.54%-- 
REPLReplimune Group8.69+4.01+85.68%-- 
CDTCDT Equity Inc.1.04+0.0899+9.46%-- 
CMNDClearmind Medicine Inc.3.58+1.13+46.12%-- 
OTLKOutlook Therapeutics0.73-0.01-1.35%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.